• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗菌药物定价。

Antimicrobial drug pricing.

作者信息

Pandey Avaneesh Kumar, Shafiq Nusrat, Kakkar Ashish Kumar, Malhotra Samir, Woods Beth, Little Christopher, Rhodes Tom, Tuson Harriet, Riaz Zeshan, Ashfield Tom, Corley Michael, Baltas Ioannis

机构信息

Department of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

Centre for Health Economics, University of York, York, UK.

出版信息

Commun Med (Lond). 2024 Oct 11;4(1):198. doi: 10.1038/s43856-024-00594-9.

DOI:10.1038/s43856-024-00594-9
PMID:39394271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11470128/
Abstract

Despite the constant development of antimicrobial resistance (AMR), few new antimicrobials are currently becoming available clinically. Alternative approaches, such as different mechanisms to fund their use, are being explored to encourage development of new antimicrobials.

摘要

尽管抗菌药物耐药性（AMR）不断发展，但目前临床上可用的新型抗菌药物却很少。人们正在探索其他方法，例如采用不同机制为其使用提供资金，以鼓励新型抗菌药物的研发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/0f07d47ee438/43856_2024_594_Fige_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/d6af104d1916/43856_2024_594_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/48562029b500/43856_2024_594_Figb_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/8cf66a00ea4a/43856_2024_594_Figc_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/65421e5dd1a5/43856_2024_594_Figd_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/0f07d47ee438/43856_2024_594_Fige_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/d6af104d1916/43856_2024_594_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/48562029b500/43856_2024_594_Figb_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/8cf66a00ea4a/43856_2024_594_Figc_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/65421e5dd1a5/43856_2024_594_Figd_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e303/11470128/0f07d47ee438/43856_2024_594_Fige_HTML.jpg

相似文献

1
Antimicrobial drug pricing.抗菌药物定价。
Commun Med (Lond). 2024 Oct 11;4(1):198. doi: 10.1038/s43856-024-00594-9.
2
Mechanisms of Antimicrobial Resistance (AMR) and Alternative Approaches to Overcome AMR.抗微生物药物耐药性（AMR）的机制及克服 AMR 的替代方法。
Curr Drug Discov Technol. 2020;17(4):430-447. doi: 10.2174/1570163816666190304122219.
3
Development and transmission of antimicrobial resistance among Gram-negative bacteria in animals and their public health impact.动物中革兰氏阴性菌抗菌药物耐药性的产生、传播及其对公共卫生的影响。
Essays Biochem. 2017 Mar 3;61(1):23-35. doi: 10.1042/EBC20160055. Print 2017 Feb 28.
4
Oral antimicrobials increase antimicrobial resistance in porcine E. coli--a systematic review.口服抗菌药物增加猪大肠杆菌的抗菌药物耐药性——系统评价。
Prev Vet Med. 2014 Mar 1;113(4):364-75. doi: 10.1016/j.prevetmed.2013.12.007. Epub 2013 Dec 27.
5
Use of Colistin and Other Critical Antimicrobials on Pig and Chicken Farms in Southern Vietnam and Its Association with Resistance in Commensal Escherichia coli Bacteria.越南南部猪场和鸡场中黏菌素及其他关键抗菌药物的使用及其与共生大肠杆菌耐药性的关联。
Appl Environ Microbiol. 2016 Jun 13;82(13):3727-3735. doi: 10.1128/AEM.00337-16. Print 2016 Jul 1.
6
Antimicrobial resistance in non-aureus staphylococci isolated from milk is associated with systemic but not intramammary administration of antimicrobials in dairy cattle.从奶牛奶中分离出的非金黄色葡萄球菌的抗微生物耐药性与奶牛系统而非乳房内使用抗微生物药物有关。
J Dairy Sci. 2018 Aug;101(8):7425-7436. doi: 10.3168/jds.2018-14540. Epub 2018 May 3.
7
Phytochemicals as Antimicrobials: Prospecting Himalayan Medicinal Plants as Source of Alternate Medicine to Combat Antimicrobial Resistance.植物化学物质作为抗菌剂：探寻喜马拉雅药用植物作为对抗抗菌药物耐药性的替代药物来源
Pharmaceuticals (Basel). 2023 Jun 15;16(6):881. doi: 10.3390/ph16060881.
8
Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE's subscription-style payment model.解决新型抗菌药物市场失灵问题的最新进展：英国国家卫生与临床优化研究所（NICE）订阅式支付模式的经验教训
Front Med Technol. 2023 Feb 13;5:1010247. doi: 10.3389/fmedt.2023.1010247. eCollection 2023.
9
Oral administration of antimicrobials increase antimicrobial resistance in E. coli from chicken--a systematic review.口服抗菌药物会增加鸡源大肠杆菌的耐药性——一项系统综述。
Prev Vet Med. 2015 Jan 1;118(1):1-7. doi: 10.1016/j.prevetmed.2014.11.010. Epub 2014 Nov 20.
10
Plant synthetic biology for producing potent phyto-antimicrobials to combat antimicrobial resistance.利用植物合成生物学生产强效植物抗菌素来对抗抗微生物药物耐药性。
Biotechnol Adv. 2021 May-Jun;48:107729. doi: 10.1016/j.biotechadv.2021.107729. Epub 2021 Mar 9.

引用本文的文献

1
Antimicrobial stewardship from a One Health perspective.从“同一健康”视角看抗菌药物管理
Nat Rev Microbiol. 2025 Sep 10. doi: 10.1038/s41579-025-01233-3.
2
Macro- and micro-influencers of antimicrobial costs…What do stewardship programs need to know?抗菌药物成本的宏观和微观影响因素……管理计划需要了解什么？
Antimicrob Steward Healthc Epidemiol. 2025 Feb 26;5(1):e68. doi: 10.1017/ash.2025.38. eCollection 2025.

本文引用的文献

1
Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study.探索英格兰感染病顾问对一种新型抗菌药物脱钩资助模式的看法：SMASH研究
JAC Antimicrob Resist. 2023 Aug 1;5(4):dlad091. doi: 10.1093/jacamr/dlad091. eCollection 2023 Aug.
2
An Insurance Value Modeling Approach That Captures the Wider Value of a Novel Antimicrobial to Health Systems, Patients, and the Population.一种保险价值建模方法，该方法可捕捉新型抗菌药物对卫生系统、患者及人群的更广泛价值。
J Health Econ Outcomes Res. 2023 Jul 18;10(2):1-9. doi: 10.36469/001c.75206. eCollection 2023.
3
Evaluating the impact of price regulation (Drug Price Control Order 2013) on antibiotic sales in India: a quasi-experimental analysis, 2008-2018.
评估价格管制（《2013年药品价格管制令》）对印度抗生素销售的影响：一项2008 - 2018年的准实验分析
J Pharm Policy Pract. 2022 Oct 22;15(1):68. doi: 10.1186/s40545-022-00466-4.
4
Antimicrobial subscription and pooled procurement.
Lancet Glob Health. 2022 May;10(5):e625. doi: 10.1016/S2214-109X(22)00091-2.
5
Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?抗菌药物耐药性：卫生技术评估是解决方案的一部分还是问题的一部分？
Value Health. 2021 Dec;24(12):1828-1834. doi: 10.1016/j.jval.2021.06.002. Epub 2021 Sep 20.
6
Shortage of essential antimicrobials: a major challenge to global health security.基本抗菌药物短缺：对全球卫生安全的重大挑战。
BMJ Glob Health. 2021 Nov;6(11). doi: 10.1136/bmjgh-2021-006961.
7
Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines.估算抗菌药物全球拉动激励措施的适当规模。
Health Aff (Millwood). 2021 Nov;40(11):1758-1765. doi: 10.1377/hlthaff.2021.00688.
8
Subscription model for antibiotic development.抗生素研发的订阅模式。
BMJ. 2019 Sep 6;366:l5364. doi: 10.1136/bmj.l5364.
9
Smallest biopharma firms are pushing more of the pipeline.规模最小的生物制药公司正在推进更多的研发项目。
Nat Rev Drug Discov. 2019 Jun;18(6):411. doi: 10.1038/d41573-019-00084-x.
10
Achaogen bankruptcy highlights antibacterial development woes.阿奇奥根公司破产凸显抗菌药物研发困境。
Nat Rev Drug Discov. 2019 Jun;18(6):411. doi: 10.1038/d41573-019-00085-w.